Results 11 to 20 of about 176,088 (291)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors

Molecular Therapy: Oncolytics, 2023
TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications to ...
Jérémy Béguin, Eve Laloy, Sandrine Cochin, Murielle Gantzer, Isabelle Farine, Christelle Pichon, Baptiste Moreau, Johann Foloppe, Jean-Marc Balloul, Christelle Machon, Jérôme Guitton, Dominique Tierny, Bernard Klonjkowski, Eric Quéméneur, Christelle Maurey, Philippe Erbs   +15 more
doaj   +1 more source

Inactivation of the lysine binding sites of human plasminogen (hPg) reveals novel structural requirements for the tight hPg conformation, M-protein binding, and rapid activation

Frontiers in Molecular Biosciences, 2023
Accelerated activation of the human plasminogen zymogen (hPg) to two-chain active plasmin (hPm) is achieved following conformational changes induced by ligand-binding at the lysine-binding sites (LBSs) in four of the five hPg kringle domains.
Yetunde A. Ayinuola, Francis J. Castellino, Francis J. Castellino   +2 more
doaj   +1 more source

Transgenic livestock

Bioscientifica Proceedings, 2019
Single genes can now be added routinely to the genome of mice by molecular manipulation as simple Mendelian dominants; this complements the normal process of reproduction to give 'transgenic' animals. Success in ruminants is limited to a few examples in sheep and although gene expression has yet to be documented, there is every reason to expect that it
J P, Simons, R B, Land
openaire   +2 more sources

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Biomedicines, 2020
As a live biologic agent, oncolytic vaccinia virus has the ability to target and selectively amplify at tumor sites. We have previously reported that deletion of thymidine kinase and ribonucleotide reductase genes in vaccinia virus can increase the ...
Franck Gallardo, Doris Schmitt, Renée Brandely, Catherine Brua, Nathalie Silvestre, Annie Findeli, Johann Foloppe, Sokunthea Top, Sandrine Kappler-Gratias, Charlotte Quentin-Froignant, Renaud Morin, Jean-Michel Lagarde, Kerstin Bystricky, Stéphane Bertagnoli, Philippe Erbs   +14 more
doaj   +1 more source

Binding of the kringle‐2 domain of human plasminogen to streptococcal PAM‐type M‐protein causes dissociation of PAM dimers

MicrobiologyOpen, 2021
The direct binding of human plasminogen (hPg), via its kringle‐2 domain (K2hPg), to streptococcal M‐protein (PAM), largely contributes to the pathogenesis of Pattern D Group A Streptococcus pyogenes (GAS).
Olawole Ayinuola, Yetunde A. Ayinuola, Cunjia Qiu, Shaun W. Lee, Victoria A. Ploplis, Francis J. Castellino   +5 more
doaj   +1 more source

Plasminogen Deficiency Significantly Reduces Vascular Wall Disease in a Murine Model of Type IIa Hypercholesterolemia

Biomedicines, 2021
The fibrinolytic system has been implicated in the genesis and progression of atherosclerosis. It has been reported that a plasminogen (Pg) deficiency (Plg−/−) exacerbates the progression of atherosclerosis in Apoe−/− mice.
Takayuki Iwaki, Tomohiro Arakawa, Mayra J. Sandoval-Cooper, Denise L. Smith, Deborah Donahue, Victoria A. Ploplis, Kazuo Umemura, Francis J. Castellino   +7 more
doaj   +1 more source

Relationships Between Plasminogen-Binding M-Protein and Surface Enolase for Human Plasminogen Acquisition and Activation in Streptococcus pyogenes

Frontiers in Microbiology, 2022
The proteolytic activity of human plasmin (hPm) is utilized by various cells to provide a surface protease that increases the potential of cells to migrate and disseminate. Skin-trophic Pattern D strains of Streptococcus pyogenes (GAS), e.g., GAS isolate
Yetunde A. Ayinuola, Sheiny Tjia-Fleck, Sheiny Tjia-Fleck, Bradley M. Readnour, Bradley M. Readnour, Zhong Liang, Olawole Ayinuola, Lake N. Paul, Shaun W. Lee, Vincent A. Fischetti, Victoria A. Ploplis, Victoria A. Ploplis, Francis J. Castellino, Francis J. Castellino   +13 more
doaj   +1 more source

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Human Vaccines & Immunotherapeutics, 2018
TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy.
Christelle Remy-Ziller, Christine Thioudellet, Julie Hortelano, Murielle Gantzer, Virginie Nourtier, Marie-Christine Claudepierre, Benoit Sansas, Xavier Préville, Kaïdre Bendjama, Eric Quemeneur, Karola Rittner   +10 more
doaj   +1 more source

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Molecular Therapy: Oncolytics, 2019
Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the tumor selectivity of these oncolytic viruses must be improved.
Johann Foloppe, Juliette Kempf, Nicolas Futin, Jacqueline Kintz, Pascale Cordier, Christelle Pichon, Annie Findeli, Fabien Vorburger, Eric Quemeneur, Philippe Erbs   +9 more
doaj   +1 more source

Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs

BMC Veterinary Research, 2021
Background 5-fluorocytosine is a pyrimidine and a fluorinated cytosine analog mainly used as an antifungal agent. It is a precursor of 5-fluorouracil, which possesses anticancer properties.
Jérémy Béguin, Matthias Kohlhauer, Eve Laloy, Frédérique Degorce, Baptiste Moreau, Éric Quéméneur, Philippe Erbs, Bernard Klonjkowski, Christelle Maurey   +8 more
doaj   +1 more source